Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
Category: #health  By Mateen Dalal  Date: 2019-09-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Inhibrx enrolls its first patient of Phase 1 trial of INBRX-101
  • INBRX-101 is built to provide greater clinical activity to pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.  
     
  • Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first six months of 2020.

Inhibrx Inc., an international biotechnology company founded in 2010 aimed at developing a pipeline of new biologic therapeutic candidates, reportedly announced the registration of first patient in its Phase 1 clinical trial of a therapeutic candidate INBRX-101 (NCT03815396).

NCT03815396 is a therapeutic candidate based on Fc-fusion protein which comprises improved recombinant iterations of human alpha-1 antitrypsin to treat alpha-1 antitrypsin deficiency, commonly called AATD, in patients.

AATD is a rare respiratory disease that is characterized by continuous impairment of lung tissue which leads to emphysema and COPD. Reports cite, approx. 100,000 people are affected by this disease across the United States with Europe numbers being at the same approximate level.

Plasma derived augmentation therapy (pdAAT), present standard of care of patients affected with AATD, has remained unchanged for several decades and depends on the weekly infusions of AAT derived from plasma purified from the human donor serum.

The company’s therapeutic candidate INBRX-101 is developed to provide greater clinical activity into pdAAT by offering sustained improved concentration of plasma within a less frequent, regimen of monthly dosing.   

CEO of Inhibrx, Mark Lappe stated that the company applied its protein engineering capabilities for overcoming the challenges associated with producing functional recombinant human alpha-1 antitrypsin, apart from identifying modifications that the company believes to be capable to optimize PK functionality and profile. Mark further added that the company is thrilled to start enrollment of Phase 1 trial to assess the potential advantages of INBRX-101 in individuals affected by AATD.

Inhibrx anticipates to unveil preliminary functional pharmacokinetic data collected during the single-dose phase of the study in the first 6 months of 2020.

 

Source credit: https://inhibrx.com/inhibrx-announces-enrollment-of-first-patient-in-phase-1-study-of-inbrx-101-a-modified-recombinant-human-aat-fc-fusion-protein/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saudi Arabia aims for net-zero carbon emissions by the year 2060
Saudi Arabia aims for net-zero carbon emissions by the year 2060
By Mateen Dalal

Global oil producer, Saudi Arabia has recently stated that it intends to reach zero greenhouse gas emission levels by 2060, thereby joining the bandwagon with other 100 countries towards limiting the impact of climate change. Although the kingdom pl...

Abbott unites with Real Madrid to aid child welfare worldwide
Abbott unites with Real Madrid to aid child welfare worldwide
By Mateen Dalal

Abbott’s partnership with Real Madrid will cater to children’s education, social welfare, sports activities in around 80 countries It will also provide health and nutritional assistance to Academy teams and product development and inn...

TotalEnergies commences its UK Offshore Wind Hub in Scotland
TotalEnergies commences its UK Offshore Wind Hub in Scotland
By Mateen Dalal

French oil and gas major, TotalEnergies SE has inaugurated its UK Offshore Wind Hub in Scotland which will be part of the company's existing offshore operations center in Aberdeen and allow employees to shift from oil and gas to offshore win...